<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03208465</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV2016-20</org_study_id>
    <nct_id>NCT03208465</nct_id>
  </id_info>
  <brief_title>Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease</brief_title>
  <acronym>ELITE</acronym>
  <official_title>Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery disease_ELITE Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHEOL WHAN LEE, M.D., Ph.D</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial evaluates the effects of Empagliflozin versus Sitagliptin, in addition to standard
      of care, on global myocardial perfusion reserve using dynamic single-photon emission computed
      tomography (SPECT) images.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in global myocardial perfusion reserve (MPR) index</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change in global myocardial perfusion reserve (MPR) index defined as (global MPR index at 6 months - global MPR index at baseline)/(global MPR index at baseline)x100.
MPR index=stress myocardial flow/rest myocardial flow</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in regional MPR index</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change in regional MPR index defined as (regional MPR index at 6 months - regional MPR index at baseline)/(regional MPR index at baseline)x100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in regional MPR index</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in global MPR index</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>Patients with Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>In empagliflozin group, patients will be prescribed empagliflozin 10mg/day.</description>
    <arm_group_label>Patients with Empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>In sitagliptin group, patients will be prescribed sitagliptin 100mg/day.</description>
    <arm_group_label>Patients with Sitagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women at least 19 years of age

          -  Type 2 diabetes mellitus

          -  Stable coronary artery disease

          -  Global myocardial perfusion reserve (MPR) index &lt; 2.0

          -  The patient or guardian agrees to the study protocol and the schedule of clinical and
             dynamic SPECT follow-up, and provides informed, written consent, as approved by the
             appropriate Institutional Review Board/Ethical Committee of the respective clinical
             site.

        Exclusion Criteria:

          -  Contraindications to empagliflozin, Sitagliptin

          -  Sodium-glucose cotransporter-2(SGLT2) inhibitors within the previous 4 weeks

          -  Insulin requiring diabetes

          -  Poor glucose control (HbA1C&gt;10 %)

          -  Acute coronary syndrome

          -  Stent placement within the previous 6 months

          -  Previous coronary artery bypass graft surgery

          -  Planned revascularization within 6 months

          -  Heart failure requiring loop diuretics

          -  Severe left ventricular hypertrophy (left ventricular septal wall thickness &gt; 13mm)

          -  Significant renal disease manifested by creatinine clearance of &lt; 30 ml/min)

          -  Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation
             (alanine transaminase or Aspartate Aminotransferase &gt; 3 times upper limit of normal)

          -  Radiopaque material implanted in the chest wall (metal, silicone, etc.)

          -  Contraindication to adenosine stress test

          -  Any clinically significant abnormality identified at the screening visit, physical
             examination, laboratory tests, or electrocardiogram which, in the judgment of the
             Investigator, would preclude safe completion of the study.

          -  Patient's pregnant or breast-feeding or child-bearing potential

          -  Expected life expectancy &lt; 1 year

          -  Unwillingness or inability to comply with the procedures described in this protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cheol-whan Lee, MD</last_name>
    <phone>82230103150</phone>
    <email>cheolwlee@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheol-whan Lee, MD</last_name>
      <phone>+82230103150</phone>
      <email>cheolwlee@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Cheol-Whan Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2017</study_first_submitted>
  <study_first_submitted_qc>July 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2017</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>CHEOL WHAN LEE, M.D., Ph.D</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Empagliflozin</keyword>
  <keyword>Sitagliptin</keyword>
  <keyword>Myocardial perfusion reserve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

